tbuckley/cabot-search huggingface dataset:
Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy
Authors: Thomas Prebet, Thomas Cluzeau, Sophie Park, Ulrich Germing, Lionel Ades, Uwe Platzbecker, Norbert Vey, Katharina Goetze, Charikleia Kelaidi, Esther Natalie Oliva, Najla H. Al Ali, Pierre Fenaux, Steven D. Gore, Rami S. Komrokji
Journal: Blood (2015)
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
Authors: Edith A. Perez, Carlos Barrios, Wolfgang Eiermann, Masakazu Toi, Young-Hyuck Im, Pierfranco Conte, Miguel Martin, Tadeusz Pienkowski, Xavier Pivot, Howard A. Burris, Jennifer A. Petersen, Sven Stanzel, Alexander Strasak, Monika Patre, Paul Ellis
Journal: Journal of Clinical Oncology (2017)

Purpose Trastuzumab and pertuzumab are human epidermal growth factor receptor 2 (HER2) –targeted monoclonal antibodies, and trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the properties of trastuzumab with the cytotoxic activity of DM1. T-DM1 demonstrated encouraging efficacy and safety in a phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Combination T-DM1 and pertuzumab showed synergistic activity in cell culture models and had an acceptable safety profile in a phase Ib and II study. Methods In the MARIANNE study, 1,095 patients with centrally assessed, HER2-positive, advanced breast cancer and no prior therapy for advanced disease were randomly assigned 1:1:1 to control (trastuzumab plus taxane), T-DM1 plus placebo, hereafter T-DM1, or T-DM1 plus pertuzumab at standard doses. Primary end point was progression-free survival (PFS), as assessed by independent review. Results T-DM1 and T-DM1 plus pertuzumab showed noninferior PFS compared with trastuzumab plus taxane (median PFS: 13.7 months with trastuzumab plus taxane, 14.1 months with T-DM1, and 15.2 months with T-DM1 plus pertuzumab). Neither experimental arm showed PFS superiority to trastuzumab plus taxane. Response rate was 67.9% in patients who were treated with trastuzumab plus taxane, 59.7% with T-DM1, and 64.2% with T-DM1 plus pertuzumab; median response duration was 12.5 months, 20.7 months, and 21.2 months, respectively. The incidence of grade ≥ 3 adverse events was numerically higher in the control arm (54.1%) versus the T-DM1 arm (45.4%) and T-DM1 plus pertuzumab arm (46.2%). Numerically fewer patients discontinued treatment because of adverse events in the T-DM1 arms, and health-related quality of life was maintained for longer in the T-DM1 arms. Conclusion T-DM1 showed noninferior, but not superior, efficacy and better tolerability than did taxane plus trastuzumab for first-line treatment of HER2-positive, advanced breast cancer.
The Road Ahead for Personalized Firearms
Authors: Joseph A. Simonetti, Ali Rowhani-Rahbar, Frederick P. Rivara
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukemia
Authors: Francesco Maura, Laura Mosca, Fabris Sonia, Giovanna Cutrona, Serena Matis, Marta Lionetti, Marzia Berbieri, Marianna Danca, Monica Colombo, Carlotta Massucco, Daniele Reverberi, Massimo Gentile, Anna Grazia Recchia, Sabrina Bossio, Fiorella Ilariucci, Caterina Musolino, Francesco Di Raimondo, Agostino Cortelezzi, Fortunato Morabito, Manlio Ferrarini, Antonino Neri
Journal: Blood (2014)
SP0105 Biochemistry and Pharmacology of The Endocannabinoid System
Authors: M. Maccarrone
Journal: Annals of the Rheumatic Diseases (2016)

Nearly 30 years after the discovery of the psychoactive ingredient of <i>Cannabis sativa</i>, Δ<sup>9</sup>-tetrahydrocannabinol (THC) in 1964, the endogenous counterparts of THC were discovered and were collectively termed endocannabinoids (eCBs). To date, among several members of the eCB family <i>N</i>-arachidonoylethanolamine (anandamide, AEA) and 2-arachidonoylglycerol (2-AG) are widely recognized as the most bioactive substances, able to bind to and activate G protein-coupled type-1 (CB<sub>1</sub>) and type-2 (CB<sub>2</sub>) cannabinoid receptors, as well as other non-CB<sub>1</sub>/non-CB<sub>2</sub> receptor targets. In addition, an ensemble of proteins that synthesize, transport and degrade eCBs have been identified in the last 20 years, altogether forming the so-called eCB system. eCBs control basic biological processes spanning from cell choice between survival and death, progenitor/stem cell proliferation and differentiation, and neurotransmission to reproductive events, energy balance and immune response. Unsurprisingly, in the last two decades eCBs have emerged as key regulators of human pathophysiology at multiple levels. Here, a modern view of the biochemistry and pharmacology of the eCB system will be presented, in order to put in a better perspective the impact of eCB signaling on human health and disease, both centrally and peripherally. In particular, it will be shown that eCBs regulate bone elongation and remodeling, as well as inflammation and adaptive/innate immunity. Moreover, unprecedented results on AEA and 2-AG alterations in human patients with systemic lupus erythematosus will be presented, that may help to better understand the role of lipid signaling in this disease. <h3>Disclosure of Interest</h3> None declared
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
Authors: Georgina V Long, Jean-Jacques Grob, Paul Nathan, Antoni Ribas, Caroline Robert, Dirk Schadendorf, Stephen R Lane, Carmen Mak, Philippe Legenne, Keith T Flaherty, Michael A Davies
Journal: The Lancet Oncology (2016)
Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study
Authors: David J. Kuter, James B. Bussel, Adrian Newland, Jeffrey S. Wasser, Roger M Lyons, James N. George, Gail Macik, Kun Nie, Susie Jun
Journal: Blood (2010)
Different In Vivo Effects of Horse and Rabbit Antithymocyte Globulin in Patients with Severe Aplastic Anemia
Authors: Xingmin Feng, Phillip Scheinberg, Angelique Biancotto, Olga Rios, Sarah Donaldson, Colin O. Wu, Haiyun Zheng, Kazuya Sato, J. Philip McCoy, Neal S. Young
Journal: Blood (2011)
Deubiquitnase BAP1 Downregulation in Myeloid Malignances: A New Pathogenic Mechanism, Dominant in Chronic Myelomonocytic Leukemia
Authors: Ana Maria Hurtado, Eva Caparrós, Jose Miguel Torregrosa, Ginés Luengo, Mara Toderici, María Eugenia De la Morena, Begoña Muiña, Maria Luisa Lozano, Constant Martinez, Mari Luz Amigo, Felipe De Arriba, Francisco Ortuño, Raul Teruel Montoya, Francisca Ferrer-Marin, Vicente Vicente, Andres Jerez
Journal: Blood (2014)
PML and PMLRARα Interact with Fas to Regulate Fas-Mediated Apoptosis In Vivo
Authors: Felipe Samaniego, Zuzana Berkova, Jillian F Wise, Celine Kerros, David H Hawke, Judith E. Karp, Hui-Kuan Lin, Jeffrey J. Molldrem, Rong-Hua Tao
Journal: Blood (2011)
THU0379 Clinical Disease Activity Measures Are Associated with Radiographic Spinal Progression in Early Axial Spondyloarthritis
Authors: D. Poddubnyy, M. Protopopov, H. Haibel, J. Braun, M. Rudwaleit, J. Sieper
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> It has been shown in the past that elevated C-reactive protein (CRP) [1] and the composite Ankylosing Spondylitis Disease Activity Score (ASDAS) [2,3] are associated with radiographic spinal progression in axial spondyloarthritis (axSpA). It is not clear, however, whether patient-reported measures of disease activity might also play a predictive role. <h3>Objectives</h3> To investigate the association between patient-reported measures of disease activity and radiographic spinal progression over two years in early axSpA. <h3>Methods</h3> Altogether 178 patients with definite axSpA (100 with ankylosing spondylitis and 78 with non-radiographic axSpA) from the German Spondyloarthritis Inception Cohort (GESPIC) were included in the current study. Spinal radiographs (cervical spine lateral views, lumbar spine lateral and anteroposterior views) were scored according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) system and for the presence of syndesmophytes. Clinical and lab data were collected at baseline and every 6 months thereafter. Time-averaged values (over 2 years) of the patient global assessment of disease activity (PG), BASDAI and its components, CRP and CRP-based ASDAS, were calculated. <h3>Results</h3> In the logistic regression analysis there was a significant association between time-averaged patient global and syndesmophyte formation (table): the adjusted odds ratio (OR) was 1.30 (1.01–1.69) meaning a 30% increase of the chance for new syndesmophytes formation over two years with an increase of PG by 1 point (on a 0–10 scale). The time-averaged BASDAI demonstrated no significant association with radiographic spinal progression, but duration and severity of morning stiffness were both significantly associated with syndesmophytes formation with a similar strength of association as the patient global (table). Similar trends although not always significant were observed for the mSASSS worsening by 2 points and more after two years. CRP and ASDAS did show an already known association with radiographic spinal progression in early axial SpA. <h3>Conclusions</h3> Higher patient global assessment of disease activity, duration and severity of morning stiffness are clinical parameters, which are associated with more radiographic spinal progression (syndesmophytes formation) in patients with early axial spondyloarthritis. <h3>References</h3> Poddubnyy D, et al. Arthritis Rheum 2012;64:1388–98. Ramiro S, et al. Ann Rheum Dis. 2014;73(8):1455–61. Poddubnyy D, eta l. Ann Rheum Dis 2014;73(Suppl2):422. <h3>Disclosure of Interest</h3> None declared
Targeted Detection of Copy Number Variants Using a Myeloid Malignancy Next Generation Sequencing Mutation Panel Allows Comprehensive Genetic Analysis Using a Single Testing Method
Authors: Wei Shen, Philippe Szankasi, Maria Sederberg, Jonathan Schumacher, Kimberly Frizzell, Elaine P Gee, Jay L Patel, Sarah T. South, Xinjie Xu, Todd W Kelley
Journal: Blood (2015)
SAT0546 Ultrasound-Detected Synovitis and Tenosynovitis Predict RA in Early Disease: Table 1.
Authors: I. Sahbudin, L. Pickup, P. Nightingale, G. Allen, Z. Cader, P. de Pablo, C.D. Buckley, K. Raza, A. Filer
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Ultrasound-detected synovitis improves the prediction of RA in early disease. Although ultrasound-detected tenosynovitis in common in early RA, its relative utility in the prediction of RA alongside ultrasound-detected synovitis and conventional serological and clinical variables is unclear. <h3>Objectives</h3> To identify a minimal core set of ultrasound, clinical and serological variables predicting RA in a cohort of patients with early arthritis using a data-driven approach. <h3>Methods</h3> 107 patients [female n=60, median age 51] with ≥1 joint with clinically apparent synovitis and a symptom duration ≤3 months underwent clinical, laboratory and ultrasound assessments. Final diagnoses were determined at 18 month follow-up. Ultrasound assessment determined the presence of synovitis at 28 joints (bilateral MCPs 1–5, PIPs 1–5, wrists, and MTPs 2–5) and tenosynovitis at four tendon sites (bilateral finger flexor and extensor carpi ulnaris tendon). First, principal component analysis (PCA) was performed on 1) clinical and serological variables (age, gender, symptom duration, ESR, CRP, RF, ACPA, duration of early morning stiffness, tender joint and swollen joint count), and 2) joint and tendon ultrasound variables. Then the variable with the highest loading factor from each component was extracted and made available in a forward step-wise multivariate logistic regression analysis. <h3>Results</h3> 46 patients developed RA, 17 developed non-RA persistent inflammatory arthritis and 44 patients had resolving disease. Seven components were identified on clinical and serological PCA and four components were identified within ultrasound synovitis and tenosynovitis variables (Table 1). The final multivariate logistic regression model included ACPA positivity (OR=12.61, CI: 3.50–45.52, p&lt;0.001), digit flexor ultrasound tenosynovitis (OR=4.58, CI: 1.67–12.56, p=0.003) and MCP 1 ultrasound synovitis positivity (OR=4.75, CI: 1.78–12.64, p=0.002). <h3>Conclusions</h3> Both ultrasound-detected synovitis and tenosynovitis provide independent data in addition to clinical and serological variables in the prediction of RA in early disease. MCP 1 and digit flexor scanning provide the optimal predictive data in this cohort. <h3>Disclosure of Interest</h3> None declared
Clinical Significance of MYC, BCL2 and BCL6 Rearrangement and Protein Expression in GCB and Non-GCB Type Diffuse Large B-Cell Lymphoma
Authors: Keisuke Kawamoto, Jun Takizawa, Hiroaki Miyoshi, Noriaki Yoshida, Yasuhiko Shibasaki, Masayoshi Masuko, Hirohito Sone, Naoya Nakamura, Koichi Ohshima
Journal: Blood (2015)
Specificity of Markers of Leukemia Initiating Cells with a New Multiparameter Flow Cytometry Based Appraoch; Impact for Prognostic and Therapeutic Applications
Authors: Gerrit J. Schuurhuis, Rolf Wouters, Angèle Kelder, Arjo P Rutten, Alexander N Snel, Monique Terwijn, Paul Noordhuis, Sonja Zweegman, Gert J. Ossenkoppele
Journal: Blood (2010)
Abstract 15370: Non-Genomic Action of Aldosterone in VSMC Requires Translocation of Mineralocorticoid Receptor to the Caveolae in the Plasma-Membrane and Subsequent Trans-Activation of Angiotensin II Type1 Receptor and its Downstream Tyrosine Kinase Pyk2/ROS/MAPKs Pathway
Authors: Shinichiro Yamaguchi, Mitsuhiko Okigaki, Hiroaki Matsubara
Journal: Circulation (2010)

Aldosterone (Aldo), known as a Na-sensitive hypertensive hormone, also promotes inflammation/fibrosis in the cardiovascular system. Aldo binds to mineralocorticoid receptor (MR) and Aldo-bound MR t...
A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.
Authors: Jennifer R. Brown, Jonathan Friedberg, Yang Feng, Kimberly Phillips, Jennifer C. Clark, Paola dal Cin, Robin Joyce, David C. Fisher, Richard I. Fisher, Ronald W. Takvorian, Jane Liesveld, Diana Marquis, Donna Neuberg, Arnold S. Freedman
Journal: Blood (2007)
FRI0343 Sleep Disorders in Patients Affected by Systemic Lupus Erythematosus (SLE) with Prolonged Inactive Disease
Authors: M. Iudici, S. Fasano, I. Pantano, L. Pierro, G. Valentini
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Sleep disturbances are frequently observed in systemic lupus erythematosus (SLE) patients, but the relationship with disease activity has not been unequivocally established. <h3>Objectives</h3> To assess the prevalence of and factors associated with sleep disorders in a cohort of SLE patients with persistent complete (no clinical activity, no serological activity and no treatment other than antimalarials) or clinical remission (only serological activity; stable immunosuppressive therapy with or without corticosteroids allowed) (1). <h3>Methods</h3> Consecutive adult SLE patients attending the outpatient clinic of the Second University of Naples were enrolled in a cross-sectional study. A complete clinical and laboratory assessment was carried out. Moreover, the Pittsburgh Sleep Quality Index (PSQI), Health Assessment Questionnaire – Disability Index (HAQ-DI), Short-Form 36 (SF-36), VAS pain, VAS fatigue, VAS global health, were administered. <h3>Results</h3> Ninety SLE patients (86 females) with a mean±SD age of 43±18 and a median disease duration of 17 years (range 2–38) were enrolled in the study. A poor sleep quality (i.e. PSQI score&gt;5) was observed in 38 (42.2%) patients, with no difference between patients in complete remission (13/30) and those in clinical remission with or without GCs (25/51; p=0.651). PSQI score was found to be significantly correlated with physical component score of SF-36 (rho -0.467, 95% CI -0.632 to -0.262; p&lt;0.0001), mental component score of SF-36 (rho -0.501, 95% CI -0.657 to -0.303; p&lt;0.0001), HAQ-DI (rho 0.497, 95% CI 0.303 to 0.651; p&lt;0.0001), VAS pain (rho 0.480, 95% CI 0.283 to 0.639; p&lt;0.0001), VAS fatigue (rho 0.491, 95% CI 0.296 to 0.697; p&lt;0.0001). No correlation was found between the physician assessment of disease activity and sleep disturbance (rho 0.113, 95% CI -0.114 to 0.128; p=0.329). <h3>Conclusions</h3> Sleep disorders are frequent in SLE patients with persistent complete or clinical remission. An impaired mental and physical quality of life, disability, fatigue and pain represent the main features associated with a low quality of sleep. <h3>References</h3> Zen M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis 2015;74:2117–22 <h3>Disclosure of Interest</h3> None declared
SF3B1, NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial
Authors: Peter Dreger, Andrea Schnaiter, Marianna Rossi, Peter Paschka, Andreas Bühler, Thorsten Zenz, Sascha Dietrich, Sebastian Böttcher, Donald Bunjes, Michael Stadler, Lutz Uharek, Christof Scheid, Ute Hegenbart, Michael Hallek, Michael Kneba, Norbert Schmitz, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood (2012)
Geriatric Assessment Driven Treatment In 149 AML Elderly Patients
Authors: Debora Capelli, Francesco Saraceni, Martina Chiarucci, Antonella Poloni, Giorgia Mancini, Silvia Trappolini, Massimo Offidani, Serena Rupoli, Mauro Montanari, Anna Rita Scortechini, Guido Gini, Ilaria Scortechini, Giancarlo Discepoli, Pietro Leoni, Attilio Olivieri
Journal: Blood (2013)
PTH-035 Does Repeat Gastroscopy for Gastric Ulceration Have an Impact On Cancer Detection and Mortality Across Lincolnshire?
Authors: NS Aslam, RJM Ingram, A Mandal
Journal: Gut (2016)

<h3>Introduction</h3> Gastric cancer typically presents late when few options for curative treatment remain. Therefore, emphasis is placed on early detection. Gastric ulceration identified at gastroscopy (OGD) can be a feature of malignancy, which is reported to cause 3% of ulcers (1). Repeat OGD to confirm ulcer healing is recommended within 6–8 weeks by NICE and within 12 weeks as a JAG quality standard. Our aim was to identify the utility of follow-up OGD in the diagnosis of gastric cancer and its impact on patient outcomes at our Trust. <h3>Methods</h3> We analysed follow-up OGDs conducted over a 14 month period (21/02/2013 to 28/04/2014) in patients with gastric ulceration identified and reported at index OGD. Endoscopies were performed at three centres (Boston, Grantham and Lincoln). We consulted electronic histology records and the EndoSoft® patient database. <h3>Results</h3> 171 patients underwent follow-up endoscopy (45% male, mean age 66 years). Two patients had underlying malignancy at follow-up OGD (gastric adenocarcinoma). Initial biopsies were negative in both. Patient one (44 years, female) was diagnosed by histology. Patient two (69 years, male) had macro- and microscopic evidence of malignancy. Staging for patient one at time of diagnosis was cT3/4 cN0 M1. She underwent explorative laparotomy, which revealed linitis plastica. She received 6 cycles of chemotherapy. The time from diagnosis to death was 436 days Patient two was staged with T3 N2 M0 disease and he underwent a total gastrectomy. Unfortunately an interval CT scan subsequently revealed metastatic spread to the liver. He died 398 days after his diagnosis. <h3>Conclusion</h3> Although our cohort was limited in size, malignancy detection rate at repeat OGD was 1.2%. Furthermore, follow-up OGD in this cohort did not impact on 5 year survival. Standardised reporting of gastric ulcer could improve local audit and be useful in JAG assessment of future OGD quality standards. The UK gastroenterology community should also consider whether recommended biopsy protocols should be implemented (2) and whether there is a cohort of our patients for whom repeat OGD can be safely avoided. <h3>References</h3> 1 Ingram, <i>et al</i>. <i>PUD Ch 56 Yamada's 6th edition</i>. 2015. 2 Loughrey BM, Johnston BT. Guidance on the effective use of upper gastrointestinal histopathology. <i>Frontline Gastroenterol</i>. <b>5</b>(2):88. <h3>Disclosure of Interest</h3> None Declared
Застосування есенціальних фосфоліпідів для лікування жирової хвороби печінки
Authors: Yu.M. Stepanov
Journal: GASTROENTEROLOGY (2016)

Передумови. З урахуванням схожості гістопатологічного патерну неалкогольної жирової хвороби печінки та алкогольної хвороби печінки було запропоновано обидва захворювання об’єднати в одну нозологічну форму під загальною назвою «жирова хвороба печінки». Методологія. При виконанні даного огляду був проведений повторний аналіз 25 досліджень, включених в огляд K.J. Gundermann зі співавт. (2016). У цих роботах вивчали ефективність і безпечність есенціальних фосфоліпідів, що були отримані з соєвих бобів і містили не менше 72 % фосфатидилхоліну. Результати. При аналізі 20 досліджень із неалкогольної жирової хвороби печінки було з’ясовано, що есенціальні фосфоліпіди зменшували вираженість симптомів, у тому числі загального нездужання, стомлюваності, нудоти, частоту болю в правому підребер’ї, здуття живота, закрепів, індекс ожиріння та товщину шкірної складки. Було відзначено позитивний вплив есенціальних фосфоліпідів на лабораторні показники плазми крові (функціональні тести печінки — аланінамінотрансфераза, аспартатамінотрансфераза, гамма-глутамілтранспептидаза, лужна фосфатаза; показники ліпідного обміну — загальний холестерин, тригліцериди, холестерин ліпопротеїнів низької щільності). Есенціальні фосфоліпіди покращували дані ультразвукового дослідження та комп’ютерної томографії печінки в 60–75 % пацієнтів. Одночасно спостерігалася ревертація гістопатологічних змін у печінці: зменшувалася вираженість стеатозу, балонування, інтраацинарного та портального запалення, що призводило до зниження стадії стеатогепатиту за класифікацією Brunt. Загальна ефективність лікування есенціальними фосфоліпідами становила 80,5 %, тоді як у групах плацебо або відсутності призначення препарату — 27,9 % (p &lt; 0,05). При вивченні 5 досліджень з алкогольної хвороби печінки були зафіксовані подібні результати, однак для їх верифікації необхідно виконати більшу кількість досліджень. Дані всіх названих вище досліджень свідчать про те, що лікування есенціальними фосфоліпідами було безпечним. Висновки. У 25 клінічних дослідженнях були підтверджені ефективність і безпека есенціальних фосфоліпідів при лікуванні жирової хвороби печінки.